Stay updated on Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page.

Latest updates to the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page
- Check4 days agoChange DetectedThe Taiwan location entry was updated from Taoyuan District to Taoyuan in the study's locations list.SummaryDifference0.0%

- Check11 days agoChange DetectedClinicalTrials.gov’s page footer revision version was updated from v3.5.2 to v3.5.3, indicating a technical/site-version change rather than an update to the study record itself.SummaryDifference0.0%

- Check18 days agoChange DetectedLiberec location entry updated from Liberecký kraj to Liberec Region (Liberec, Czechia, 460 63); Ono Pharmaceutical Co. Ltd changed to Ono Pharmaceutical Co., Ltd, and the revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedDifference0.0%

- Check47 days agoChange DetectedAdded Naples, Italy, 80131 as a study site and removed Napoli, Italy, 80131 to standardize location naming. Updated the Publications section with the Lancet Oncology 2019 extended follow-up citation and removed the related erratum entries.SummaryDifference0.1%

- Check61 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page.